The four being recalled are Zantac 150mg/10ml Syrup, Zantac 50mg/2ml Injection, Zantac 150mg Tablets and Zantac 300mg Tablets. But patients should keep taking their prescribed medicine ...

(WJET/WFXP) — UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 ...

(Reuters) -GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company ...

It follows concern in several countries over the presence of impurities in Zantac and other ranitidine products. Canada and France have already announced Zantac recalls. The US and the European ...

Corrects headline to say 'settlements' instead of 'settlement' British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

Zantac, first sold in the US in 1983, was one of the best-selling medicines globally, bringing in more than $1bn (€0.91bn) in sales per year. It was also sold by Sanofi, a French drug company ...

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen.

GSK shares jumped more than 5 per cent on Thursday after the pharma giant said it will pay up to £1.7billion to settle thousands of legal cases that claimed its heartburn drug Zantac caused cancer.